In the randomized, phase 3 RATIONALE-306 trial (NCT03783442), tislelizumab + CT demonstrated more favorable overall survival (OS) outcomes and a manageable safety profile relative to placebo + CT as 1L treatment of advanced or metastatic ESCC in the intent-to-treat (ITT) population, with the greatest OS benefit being observed in patients with a tumor PD-L1 TAP score ≥10% (secondary endpoint analysis) (21). This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.